Research advances in pharmacological prevention of pancreatitis after endoscopic retrograde cholangiopancreatography

Wang Ai; Zhao LiJin

doi:10.3969/j.issn.1001-5256.2017.01.043

Issue 1

Jan. 2017

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2017 > 33(1): 184-187

PDF( 1477 KB)

Research advances in pharmacological prevention of pancreatitis after endoscopic retrograde cholangiopancreatography

DOI: 10.3969/j.issn.1001-5256.2017.01.043

Wang Ai,
Zhao LiJin

Zunyi Medical College, Zunyi, Guizhou 563003, China

Published Date: 2017-01-20

Abstract

Abstract

Endoscopic retrograde cholangiopancreatography( ERCP) has become an important method for the diagnosis and treatment of cholangio- pancreatic duct diseases. Post- ERCP pancreatitis( PEP) is the most common complication and its incidence has increased up to 40% in recent years. The prevention of PEP has always been a hot topic in clinical research. This article reviews the research advances in the pharmacological prevention of PEP and points out that controlled clinical trials with a large sample size are still needed to investigate the effect of preventive drugs,and further studies should focus on optimal medication time,route of administration,and dose. In addition,demographic features of populations from different countries and different age groups should be taken into consideration.
- pancreatitis,
- cholangiopancreatography,
- endoscopic retrograde,
- chemoprevention

FullText(HTML)

References(41)

References

[1] Chinese Society of Digestive Endoscopy,Chinese Medical Association Pancreatic Disease Committee of Chinese Medical Doctor Association.Expert consensus on pharmacological prevention of pancreatitis after endoscopic retrograde cholangiopancreatography(2015,Shanghai)[J].J Clin Hepatol,2016,32(5):830-834.(in Chinese)中华医学会消化内镜学分会,中国医师协会胰腺病专业委员会.内镜下逆行胰胆管造影术后胰腺炎药物预防专家共识意见(2015年,上海)[J].临床肝胆病杂志,2016,32(5):830-834.

[2]TESTONI PA,MARIANI A,GIUSSANI A,et al.Risk factors for post-ERCP pancreatitis in high-and low-volume centers and among expert and non-expert operators:a prospective multicenter study[J].Am J Gastroenterol,2010,105(8):1753-1761.

[3]GOTTLIEB K,SHERMAN S.ERCP and biliary endoscopic sphincterotomy-induced pancreatitis[J].Gastrointest Endosc Clin N Am,1998,8(1):87-114.

[4]FREEMAN ML.Adverse outcomes of endoscopic retrograde cholangiopancreatography:avoidance and management[J].Gastrointest Endosc Clin N Am,2003,13(4):775-798.

[5]COTTON PB,LEHMAN G,VENNES J,et al.Endoscopic sphincterotomy complications and their management:an attempt at consensus[J].Gastrointest Endosc,1991,37(3):383-393.

[6]FREEMAN ML,NELSON DB,SHERMAN S,et al.Complications of endoscopic biliary sphincterotomy[J].N Engl J Med,1996,335(13):909-918.

[7]BANKS PA,BOLLEN TL,DERVENIS C,et al.Classification of acute pancreatitis—2012:revision of the Atlanta classification and definitions by international consensus[J].Gut,2013,62(1):102-111.

[8]ARTIFON EL,CHU A,FREEMAN M,et al.A comparison of the consensus and clinical definitions of pancreatitis with a proposal to redefine post-endoscopic retrograde cholangiopancreatography pancreatitis[J].Pancreas,2010,39(4):530-535.

[9]DELLINGER EP,FORSMARK CE,LAYER P,et al.Determinant-based classification of acute pancreatitis severity:an international multidisciplinary consultation[J].Ann Surg,2012,256(6):875-880.

[10]GEORGE S,KULKARNI AA,STEVENS G,et al.Role of osmolality of contrast media in the development of post-ERCP pancreatitis:a metanalysis[J].Dig Dis Sci,2004,49(3):503-508.

[11]YIERPAN AS,GAO F.Risk factors for hyperamylasemia after endoscopic retrograde cholangiopancreatography[J].J Clin Hepatol,2016,32(1):119-122.(in Chinese)依尔潘·艾山,高峰.经内镜逆行胰胆管造影术后高淀粉酶血症的危险因素分析[J].临床肝胆病杂志,2016,32(1):119-122.

[12]DING X,ZHANG F,WANG Y.Risk factors for post-ERCP pancreatitis:a systematic review and meta-analysis[J].Surgeon,2015,13(4):218-229.

[13]ANDRIULLI A,LOPERFIDO S,NAPOLITANO G,et al.Incidence rates of post-ERCP complications:a systematic survey of prospective studies[J].Am J Gastroenterol,2007,102(8):1781-1788.

[14]ANDRADE-DAVILA VF,CHAVEZ-TOSTADO M,DAVALOSCOBIAN C,et al.Rectal indomethacin versus placebo to reduce the incidence of pancreatitis after endoscopic retrograde cholangiopancreatography:results of a controlled clinical trial[J].BMC Gastroenterol,2015,15:85.

[15]PATIL S,PANDEY V,PANDAV N,et al.Role of rectal diclofenac suppository for prevention and its impact on severity of postendoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients[J].Gastroenterology Res,2016,9(2-3):47-52.

[16]LEVENICK JM,GORDON SR,FADDEN LL,et al.Rectal indomethacin does not prevent post-ercp pancreatitis in consecutive patients[J].Gastroenterology,2016,150(4):911-917.

[17]PARK SW,CHUNG MJ,OH TG,et al.Intramuscular diclofenac for the prevention of post-ERCP pancreatitis:a randomized trial[J].Endoscopy,2015,47(1):33-39.

[18]DUMONCEAU JM,ANDRIULLI A,DEVIERE J,et al.European Society of Gastrointestinal Endoscopy(ESGE)guideline:prophylaxis of post-ERCP pancreatitis[J].Endoscopy,2010,42(6):503-515.

[19]HANNA MS,PORTAL AJ,DHANDA AD,et al.UK wide survey on the prevention of post-ERCP pancreatitis[J].Frontline Gastroenterol,2014,5(2):103-110.

[20]DUMONCEAU JM,ANDRIULLI A,ELMUNZER BJ,et al.Prophylaxis of post-ERCP pancreatitis:European Society of Gastrointestinal Endoscopy(ESGE)guideline-updated June 2014[J].Endoscopy,2014,46(9):799-815.

[21]AKBAR A,ABU DAYYEH BK,BARON TH,et al.Rectal nonsteroidal anti-inflammatory drugs are superior to pancreatic duct stents in preventing pancreatitis after endoscopic retrograde cholangiopancreatography:a network meta-analysis[J].Clin Gastroenterol Hepatol,2013,11(7):778-783.

[22]de QUADROS ONOFRIO F,LIMA JC,WATTE G,et al.Prophylaxis of pancreatitis with intravenous ketoprofen in a consecutive population of ERCP patients:a randomized double-blind placebo-controlled trial[J].Surg Endosc,2016.[Epub ahead of print]

[23]ANDRIULLI A,LEANDRO G,NIRO G,et al.Pharmacologic treatment can prevent pancreatic injury after ERCP:a meta-analysis[J].Gastrointest Endos,2000,51(1):1-7.

[24]ANDRIULLI A,CARUSO N,QUITADAMO M,et al.Antisecretory vs.antiproteasic drugs in the prevention of post-ERCP pancreatitis:the evidence-based medicine derived from a meta-analysis study[J].JOP,2003,4(1):41-48.

[25]ANDRIULLI A,LEANDRO G,FEDERICI T,et al.Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP:an updated meta-analysis[J].Gastrointest Endos,2007,65(4):624-632.

[26]DEENADAYALU VP,BLAUT U,WATKINS JL,et al.Does obesity confer an increased risk and/or more severe course of post-ERCP pancreatitis:a retrospective,multicenter study[J].J Clin Gastroenterol,2008,42(10):1103-1109.

[27]ZHANG Y,CHEN QB,GAO ZY,et al.Meta-analysis:octreotide prevents post-ERCP pancreatitis,but only at sufficient doses[J].Aliment Pharmacol Ther,2009,29(11):1155-1164.

[28]QIN X,LEI WS,XING ZX,et al.Prophylactic effect of somatostatin in preventing Post-ERCP pancreatitis:an updated meta-analysis[J].Saudi J Gastroenterol,2015,21(6):372-378.

[29]YUHARA H,OGAWA M,KAWAGUCHI Y,et al.Pharmacologic prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis:protease inhibitors and NSAIDs in a meta-analysis[J].J Gastroenterol,2014,49(3):388-399.

[30]LUMAN W,PRYDE A,HEADING RC,et al.Topical glyceryl trinitrate relaxes the sphincter of Oddi[J].Gut,1997,40(4):541-543.

[31]STARITZ M,PORALLA T,EWE K,et al.Effect of glyceryl trinitrate on the sphincter of Oddi motility and baseline pressure[J].Gut,1985,26(2):194-197.

[32]BRANDSTATTER G,SCHINZEL S,WURZER H.Influence of spasmolytic analgesics on motility of sphincter of Oddi[J].Dig Dis Sci,1996,41(9):1814-1818.

[33]DING J,JIN X,PAN Y,et al.Glyceryl trinitrate for prevention of post-ERCP pancreatitis and improve the rate of cannulation:a meta-analysis of prospective,randomized,controlled trials[J].PLo S One,2013,8(10):e75645.

[34]KUBILIUN NM,ADAMS MA,AKSHINTALA VS,et al.Evaluation of pharmacologic prevention of pancreatitis after endoscopic retrograde cholangiopancreatography:a systematic review[J].Clin Gastroenterol Hepatol,2015,13(7):1231-1239.

[35]SHAO LM,CHEN QY,CHEN MY,et al.Nitroglycerin in the prevention of post-ERCP pancreatitis:a meta-analysis[J].Dig Dis Sci,2010,55(1):1-7.

[36]LEE TY,CHOI JS,OH HC,et al.Oral udenafil and aceclofenac for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients:a randomized multicenter study[J].Korean J Intern Med,2015,30(5):602-609.

[37]CHOI JH,KIM HJ,LEE BU,et al.Vigorous periprocedural hydration with lactated ringer's solution reduces the risk of pancreatitis after retrograde cholangiopancreatography in hospitalized patients[J].Clin Gastroenterol Hepatol,2017,15(1):86-92.

[38]ELMUNZER BJ.Aggressive intravenous fluid resuscitation for preventing post-endoscopic retrograde cholangiopancreatography pancreatitis:finally on the right track[J].Clin Gastroenterol Hepatol,2014,12(2):308-310.

[39]GRUNWALD D,WADHWA V,SAWHNEY MS.Hemodynamic variation and intravenous fluids administered during ERCP and the association with post-ERCP pancreatitis[J].Pancreas,2016,45(2):293-297.

[40]GOOSHE M,ABDOLGHAFFARI AH,NIKFAR S,et al.Antioxidant therapy in acute,chronic and post-endoscopic retrograde cholangiopancreatography pancreatitis:an updated systematic review and meta-analysis[J].World J Gastroenterol,2015,21(30):9189-9208.

[41]FUENTES-OROZCO C,DAVALOS-COBIAN C,GARCIACORREA J,et al.Antioxidant drugs to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis:what does evidence suggest?[J].World J Gastroenterol,2015,21(21):6745-6753.

Relative Articles

[1]	Di WU, Dahua DAI, Wenmei LIANG, Bao FU, Xiaoyun FU. Clinical features of acute pancreatitis in pregnancy and related risk factors[J]. Journal of Clinical Hepatology, 2024, 40(5): 1009-1015. doi: 10.12449/JCH240522
[2]	Chengsi ZHAO, Weijie YAO, Peng YUAN, Zuozheng WANG. Time distribution of risk factors for secondary pancreatic infection in acute pancreatitis[J]. Journal of Clinical Hepatology, 2022, 38(7): 1686-1690. doi: 10.3969/j.issn.1001-5256.2022.07.044
[3]	Yu LIANG, Yuanhong ZHAO, Zheng LI. Recent advancement in research on intrahepatic cholangiocarcinoma: Risk factors and pathogenesis[J]. Journal of Clinical Hepatology, 2022, 38(10): 2391-2395. doi: 10.3969/j.issn.1001-5256.2022.10.037
[4]	Hongyu XIANG, Zheng DANG, Shulin XU, Gang NIU, Yuesheng LI, Baiwen MIAO, Yaoping PANG, Ruifang FAN, Jianwei QIN. A multivariate analysis of acute severe cholangitis and the establishment and evaluation of a risk prediction scoring model[J]. Journal of Clinical Hepatology, 2022, 38(8): 1847-1853. doi: 10.3969/j.issn.1001-5256.2022.08.024
[5]	Yu LIU, Xue MEI, Yuyi ZHANG, Ying ZOU, Zhengguo ZHANG, Hongying GUO, Wei YUAN, Jiefei WANG, Zhiping QIAN. Clinical features and risk factors of acute hepatitis E with severe jaundice[J]. Journal of Clinical Hepatology, 2021, 37(3): 565-569. doi: 10.3969/j.issn.1001-5256.2021.03.013
[6]	Jiali MA, Yu JIANG, Julong HU, Zhenglin AI, Lingling HE, Yuling ZHOU, Xiuxia LIANG, Yijun LIN, Hongshan WEI, Ping LI. Risk factors for rebleeding after endoscopic selective variceal devascularization in patients with hepatitis B cirrhosis and acute variceal bleeding[J]. Journal of Clinical Hepatology, 2021, 37(11): 2569-2574. doi: 10.3969/j.issn.1001-5256.2021.11.017
[7]	Yuling DUAN, Zanjie FENG, Guoxin FAN, Lei WANG, Kangwei LIU, Cijun PENG. Risk factors for open pancreatic necrosectomy in patients with severe acute pancreatitis: An analysis based on the surgical step-up approach[J]. Journal of Clinical Hepatology, 2021, 37(4): 893-897. doi: 10.3969/j.issn.1001-5256.2021.04.033
[8]	Yang DongXiao, Zhang Yong, Wang XueFeng, Li Jiang. Application of ultrasound-guided real-time percutaneous transhepatic-cholangial or transhepatic-cholecyst drainage in treatment of acute obstructive cholangitis in primary hospitals[J]. Journal of Clinical Hepatology, 2020, 36(4): 847-849. doi: 10.3969/j.issn.1001-5256.2020.04.027
[9]	Wang CaiBin, Su Yang. Risk factors for posthepatectomy liver failure and related prevention and treatment methods[J]. Journal of Clinical Hepatology, 2020, 36(9): 2119-2124. doi: 10.3969/j.issn.1001-5256.2020.09.048
[10]	Cao Yuan, Yao GuoXiang, Shi YiHai. An excerpt of international consensus guidelines for risk factors in chronic pancreatitis (2020)[J]. Journal of Clinical Hepatology, 2020, 36(8): 1720-1722. doi: 10.3969/j.issn.1001-5256.2020.08.008
[11]	Ren XiaoYing, Wu YongBiao, Ding XiangYuan, Li Xue, Yan HuiMing. Clinical effect of endoscopic sphincterotomy with balloon dilation versus sphincterotomy alone in treatment of large common bile duct stones: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(4): 850-854. doi: 10.3969/j.issn.1001-5256.2020.04.028
[12]	Wang JunMin, Ren WeiRui, Meng Xia, Zhao LiWei, Jiang Tao. Research advances in the impairment of Oddi sphincter function caused by endoscopic sphincterotomy[J]. Journal of Clinical Hepatology, 2020, 36(2): 468-471. doi: 10.3969/j.issn.1001-5256.2020.02.052
[13]	Shi BaoPing, Fu Yan, Lu MingLiang, Liu GuoBin, Li XinHua, Wei Li, Hu YiTao, Yang Juan. Clinical effect of different methods for endoscopic precut sphincterotomy in difficult intubation during endoscopic retrograde cholangiopancreatography: A comparative analysis[J]. Journal of Clinical Hepatology, 2019, 35(8): 1760-1765. doi: 10.3969/j.issn.1001-5256.2019.08.022
[14]	Wang ChunQiu, Ma YingCai, Zhu ZhiYong, Yuan Ling. Risk factors for pyogenic cholangitis in patients with common bile duct stones[J]. Journal of Clinical Hepatology, 2017, 33(1): 95-97. doi: 10.3969/j.issn.1001-5256.2017.01.020
[15]	YIERPAN Aishan, Gao Feng. Risk factors for hyperamylasemia after endoscopic retrograde cholangiopancreatography[J]. Journal of Clinical Hepatology, 2016, 32(1): 119-122. doi: 10.3969/j.issn.1001-5256.2016.01.022
[16]	Zhang Yi, Zhang JieFeng, Zhang YanLin, Zhang Xi, Ceng JianTing, Deng HeJun. Risk factors for acute liver failure after radical surgery combined with hemihepatectomy for hilar cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2016, 32(10): 1936-1938. doi: 10.3969/j.issn.1001-5256.2016.10.023
[17]	Ding ShiHua, Wu DongHai, Guo HaiJian, Liu Jun. Risk factors for long-term complications after endoscopic sphincterotomy for benign biliary and pancreatic diseases[J]. Journal of Clinical Hepatology, 2016, 32(5): 918-920. doi: 10.3969/j.issn.1001-5256.2016.05.022
[18]	Zhang RuoYan, Du XiaoHong, Wang Meng, Ye JunFeng, Jin GuoXing, Wang GuangYi. Severe thrombocytopenia in AOSC after ERCP: a report of one case[J]. Journal of Clinical Hepatology, 2014, 30(4): 373-374. doi: 10.3969/j.issn.1001-5256.2014.04.022
[19]	Huang YunFei, Li ZhaoXin, Liu MingHui, Fu JiNing. Application of precutsphincterotomy for endoscopic retrograde cholangiopancreatography with difficult biliary cannulation[J]. Journal of Clinical Hepatology, 2014, 30(12): 1344-1346. doi: 10.3969/j.issn.1001-5256.2014.12.027
[20]	Dou WeiJia, Zhou Lin, Wu KaiChun. Risk factors of chronic pancreatitis[J]. Journal of Clinical Hepatology, 2011, 27(11): 1180-1183.

Supplements(0)

Cited By

Cited by

Periodical cited type(5)

1.	张彦，王国英. 经内镜逆行胰胆管造影术联合内镜下十二指肠乳头括约肌切开术胆总管取石术后胆总管结石复发危险因素分析. 山西医药杂志. 2020(03): 290-292 .
2.	曾婷. 十二指肠镜重复消毒法对经内镜逆行胰胆管造影患者术后胆管炎的预防效果. 实用临床医药杂志. 2020(16): 50-52 .
3.	吴莉莉，覃刚，朱鹏，朱季香. 鼻胆引流管经内镜剪断后残端用于治疗胆管癌相关恶性胆管梗阻60例. 中国临床保健杂志. 2020(05): 644-648 .
4.	张科，黄国进，李江虹，陆志平，成翠娥，曾远程，肖龙，陆芬英，王斌. 内镜下乳头括约肌小切开联合球囊扩张术对异常乳头的胆总管结石疗效分析. 齐齐哈尔医学院学报. 2018(12): 1388-1390 .
5.	殷秀碧. 老年十二指肠镜下乳头切开胆管取石术中预见性护理的应用分析. 结直肠肛门外科. 2018(S2): 245-246 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2132) PDF downloads(402)

Research advances in pharmacological prevention of pancreatitis after endoscopic retrograde cholangiopancreatography

DOI: 10.3969/j.issn.1001-5256.2017.01.043